What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Heart failure
- Cardiology
Gerasimos Filippatos mainly investigates Heart failure, Internal medicine, Cardiology, Intensive care medicine and Ejection fraction.
His Heart failure research is multidisciplinary, relying on both Heart disease and Blood pressure.
Many of his studies involve connections with topics such as Endocrinology and Internal medicine.
His work on Atrial fibrillation, Coronary artery disease and Cardiac resynchronization therapy as part of general Cardiology research is frequently linked to Risk assessment, bridging the gap between disciplines.
His Intensive care medicine research incorporates elements of Volume overload, Clinical trial and Epidemiology.
His Ejection fraction study also includes
- Anemia that intertwine with fields like Placebo and Adverse effect,
- Spironolactone and related Kidney disease.
His most cited work include:
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. (9345 citations)
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (3899 citations)
- Guidelines on the management of valvular heart disease The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (3367 citations)
What are the main themes of his work throughout his whole career to date?
Gerasimos Filippatos focuses on Heart failure, Internal medicine, Cardiology, Ejection fraction and Intensive care medicine.
His study in Heart failure is interdisciplinary in nature, drawing from both Clinical trial, Blood pressure, Hazard ratio, Confidence interval and Placebo.
His work on Natriuretic peptide, Atrial fibrillation and Myocardial infarction is typically connected to In patient as part of general Internal medicine study, connecting several disciplines of science.
His work deals with themes such as Serelaxin, Surgery and Renal function, which intersect with Cardiology.
His research in Ejection fraction intersects with topics in Empagliflozin, Quality of life, Anemia and Diastole.
He regularly links together related areas like Epidemiology in his Intensive care medicine studies.
He most often published in these fields:
- Heart failure (79.49%)
- Internal medicine (77.87%)
- Cardiology (62.75%)
What were the highlights of his more recent work (between 2019-2021)?
- Heart failure (79.49%)
- Internal medicine (77.87%)
- Cardiology (62.75%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Heart failure, Internal medicine, Cardiology, Ejection fraction and In patient.
His research in Heart failure is mostly focused on Natriuretic peptide.
His Natriuretic peptide course of study focuses on Troponin and Biomarker.
Internal medicine is often connected to Diabetes mellitus in his work.
His research in Cardiology focuses on subjects like Type 2 diabetes, which are connected to Finerenone.
His research investigates the connection with Ejection fraction and areas like Empagliflozin which intersect with concerns in Dapagliflozin and Clinical endpoint.
Between 2019 and 2021, his most popular works were:
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASDThe Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD) (719 citations)
- 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) (424 citations)
- Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. (203 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Heart failure
- Cardiology
His primary scientific interests are in Heart failure, Internal medicine, Ejection fraction, Cardiology and Empagliflozin.
His Heart failure research includes elements of Renal function, Renin–angiotensin system, Randomized controlled trial, Prospective cohort study and Cohort.
Gerasimos Filippatos undertakes multidisciplinary studies into Internal medicine and In patient in his work.
His work carried out in the field of Ejection fraction brings together such families of science as Independent predictor, Membrane transport protein, Transporter, Cardiac function curve and Placebo.
Stroke volume is closely connected to Omecamtiv mecarbil in his research, which is encompassed under the umbrella topic of Cardiology.
His work investigates the relationship between Empagliflozin and topics such as Dapagliflozin that intersect with problems in Canagliflozin.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
